FDA approves first drug to treat hallucinations in Parkinson’s psychosis
Pimavanserin on April 29 became the first drug to receive approval from the Food and Drug Administration for the indication of hallucinations and delusions associated with psychosis in Parkinson’s...
Source: Clinical Psychiatry News - Category: Psychiatry Source Type: research
More News: Food and Drug Administration (FDA) | Psychiatry